VALUE: analysis of results.

In the VALUE trial, new-onset diabetes arose in significantly fewer hypertensive patients on valsartan, an angiotensin receptor AT1 blocker (ARB), than on amlodipine, a metabolically neutral calcium-channel blocker, after a mean follow-up of 4.2 years. This finding confirms and extends the results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in which the incidence of diabetes was lower in hypertensive patients on lisinopril, an angiotensin converting enzyme (ACE) inhibitor, than on amlodipine. In ALLHAT, the between-group difference was even greater when lisinopril was compared with the diuretic chlorthalidone.